ModernMedicine Resource Center More Topics

generics

Industry pushes for faster generic approvals as costs riseGeneric drugmakers and others are pushing for faster FDA approval of generics.
Will docs prescribe the new RA biosimilars?While FDA recently approved two new biosimilars for rheumatoid arthritis and other inflammatory diseases, questions remain about how quickly physicians and patients will embrace the new drugs.
Five specialty pharmaceutical trends to watchApprovals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.
Study: New cholesterol drugs cost 356 times more than genericsA report from the Alliance of Community Health Plans can help get a better sense of how well drugs help patients compared to other treatment options.
Medicare drug spending spike shows need for genericsAn exclusive Associated Press report found that Medicare’s spending on certain drugs soared by 85% in two years.
What the new biosimilar means for U.S. healthcarePhysicians and pharmacists welcomed FDA’s recent approval of etanercept-szzs (Erelzi), a biosimilar to Amgen’s top-selling Enbrel for rheumatoid arthritis, plaque psoriasis, and other inflammatory conditions.
Biosimilar naming method questionedFDA’s method for naming biosimilars and interchangeable biologics came under fire long before the first biosimilar, Zarxio, was approved last spring.
Study: Biosimilars as safe as branded drugsNew study finds that biosimilar medications for arthritis and other diseases areas safe and effective as their brand-name counterparts.
Global generics drug market to grow 10% annuallyPatents expire, competition rises, and outsourcing expands.
New bill aims to support generic, biosimilar drug competitionThe CREATES Act came about because some pharmaceutical manufacturers are misusing the REMS program to prevent generic drug development.